Finance

Beta
Lists
LUNA:VIE
H Lundbeck A/S Class A
€5.03
+1.41%
(+0.070) 1D
Jun 4, 5:36:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for LUNA...
Open
€4.98
High
€5.03
Low
€4.96
Mkt. cap
42.59B
Avg. vol.
189.00
Volume
0.00
52-wk high
€5.32
52-wk low
€3.84
No. of employees
5K
Open
€4.98
High
€5.03
Low
€4.96
Mkt. cap
42.59B
Avg. vol.
189.00
Volume
0.00
52-wk high
€5.32
52-wk low
€3.84
No. of employees
5K
News stories
From sources across the web
Profile
H. Lundbeck A/S, commonly referred to as Lundbeck, is a Danish international pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at brain diseases, including depression, schizophrenia, Alzheimer's disease, Parkinson's disease and migraine. Wikipedia
About H Lundbeck A/S Class A
CEOCharl Van Zyl
Employees5K
FoundedAug 14, 1915
Headquarters-
SectorPharmaceutical industry
Websitelundbeck.com
Previous reportsAll values in DKK
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in DKK
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
6.02B
6.28B
6.09B
7.12B
Cost of goods sold
1.09B
846.00M
1.24B
1.30B
Cost of revenue
1.09B
846.00M
1.24B
1.30B
Research and development expenses
1.06B
1.16B
820.00M
1.38B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.30B
2.15B
2.54B
2.13B
Operating expense
3.36B
3.31B
4.36B
3.67B
Total operating expenses
4.45B
4.16B
5.60B
4.97B
Operating income
1.57B
2.12B
490.00M
2.16B
Other non operating income
-
-
-32.00M
-
EBT including unusual items
1.24B
1.41B
360.00M
2.13B
EBT excluding unusual items
1.24B
1.90B
567.00M
2.13B
Income tax expense
272.00M
311.00M
387.00M
468.00M
Effective tax rate
21.97%
22.03%
107.50%
22.01%
Other operating expenses
-
-
997.00M
152.00M
Net income
966.00M
1.10B
-27.00M
1.66B
Net profit margin
16.04%
17.53%
-0.44%
23.27%
Earnings per share
1.35
1.44
0.94
2.16
Interest and investment income
-
-
199.00M
-
Interest expense
-333.00M
-219.00M
-83.00M
-29.00M
Net interest expenses
-333.00M
-219.00M
116.00M
-29.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
2.01B
2.55B
956.00M
2.63B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer